Cargando…

Clinical and cost outcomes following genomics‐informed treatment for advanced cancers

BACKGROUND: Single‐arm trials are common in precision oncology. Owing to the lack of randomized counterfactual, resultant data are not amenable to comparative outcomes analyses. Difference‐in‐difference (DID) methods present an opportunity to generate causal estimates of time‐varying treatment outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weymann, Deirdre, Pollard, Samantha, Chan, Brandon, Titmuss, Emma, Bohm, Alexandra, Laskin, Janessa, Jones, Steven J. M., Pleasance, Erin, Nelson, Jessica, Fok, Alexandra, Lim, Howard, Karsan, Aly, Renouf, Daniel J., Schrader, Kasmintan A., Sun, Sophie, Yip, Stephen, Schaeffer, David F., Marra, Marco A., Regier, Dean A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335838/ https://www.ncbi.nlm.nih.gov/pubmed/34152087 http://dx.doi.org/10.1002/cam4.4076

Ejemplares similares

The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers
por: Weymann, Deirdre, et al.
Publicado: (2017)

Matching methods in precision oncology: An introduction and illustrative example
por: Weymann, Deirdre, et al.
Publicado: (2020)

Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care
por: Weymann, Deirdre, et al.
Publicado: (2021)

Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology
por: Dixon, Katherine, et al.
Publicado: (2020)

Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication
por: Pollard, Samantha, et al.
Publicado: (2020)

Development and early‐stage evaluation of a patient portal to enhance familial communication about hereditary cancer susceptibility testing: A patient‐driven approach
por: Pollard, Samantha, et al.
Publicado: (2023)

Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing
por: Thibodeau, My Linh, et al.
Publicado: (2020)

CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome
por: Cremin, Carol, et al.
Publicado: (2018)

TMBur: a distributable tumor mutation burden approach for whole genome sequencing
por: Titmuss, Emma, et al.
Publicado: (2022)

Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers
por: Laskin, Janessa, et al.
Publicado: (2015)

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
por: Tsang, Erica S., et al.
Publicado: (2023)

Genetic matching for time-dependent treatments: a longitudinal extension and simulation study
por: Weymann, Deirdre, et al.
Publicado: (2023)

Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy
por: Zhang, Yiqun, et al.
Publicado: (2021)

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant
por: Majounie, Elisa, et al.
Publicado: (2020)

Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
por: Naso, Julia R., et al.
Publicado: (2020)

Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis
por: Thibodeau, My Linh, et al.
Publicado: (2019)

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
por: Regier, Dean A., et al.
Publicado: (2022)

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing
por: Wong, Hui-li, et al.
Publicado: (2018)

“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management
por: Shickh, Salma, et al.
Publicado: (2022)

Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2018)

Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2017)

Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing
por: Parker, Jeremy D.K., et al.
Publicado: (2016)

The pivotal role of sampling recurrent tumors in the precision care of patients with tumors of the central nervous system
por: Wong, Derek, et al.
Publicado: (2019)

Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
por: Kwon, Janice S., et al.
Publicado: (2022)

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
por: Pender, Alexandra, et al.
Publicado: (2020)

Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System
por: Richardson, Matthew, et al.
Publicado: (2020)

Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
por: Chahal, Manik, et al.
Publicado: (2018)

Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment
por: Weymann, Deirdre, et al.
Publicado: (2018)

Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer
por: Tsang, Erica S., et al.
Publicado: (2019)

Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening
por: Cremin, Carol, et al.
Publicado: (2020)

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases
por: Owen, Daniel R., et al.
Publicado: (2018)

Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury
por: Williamson, Laura M., et al.
Publicado: (2021)

Detection and genomic characterization of a mammary-like adenocarcinoma
por: Grewal, Jasleen K., et al.
Publicado: (2017)

Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2018)

NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profiling
por: Britton, Heidi M., et al.
Publicado: (2021)

Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma
por: Ko, Jenny J., et al.
Publicado: (2018)

Heterogeneity of breast cancer stem cells as evidenced with Notch-dependent and Notch-independent populations
por: Wong, Nelson K Y, et al.
Publicado: (2012)

A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
por: Regier, Dean A., et al.
Publicado: (2022)

Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer
por: Jones, M. R., et al.
Publicado: (2016)

Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome Sequencing
por: Sheffield, Brandon S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bkkedsgiol0j00gcv531okpdbl